Diagnostic and molecular aspects of adrenal cortical tumors

Seminars in Diagnostic Pathology

Volumn 30, Issue 3, 2013, Pages 197-206

  McNicol, Anne Marie ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Adenoma; Adrenal cortex; Carcinoma; Molecular

Indexed keywords

CORTICOTROPIN; CYCLIC AMP; KI 67 ANTIGEN; PROTEIN P53; SOMATOMEDIN B;

ACTH INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA; ACTH SECRETING ADENOMA; ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX TUMOR; ADRENAL HYPERPLASIA; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CLINICAL FEATURE; COMPARATIVE GENOMIC HYBRIDIZATION; CUSHING SYNDROME; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; ECTOPIC CORTICOTROPIN PRODUCTION; FEMINIZATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; IGF 2 GENE; IMMUNOHISTOCHEMISTRY; MODIFIED WEISS INDEX; MOLECULAR EVOLUTION; OVERALL SURVIVAL; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; SOMATIC MUTATION; STEROID RELEASE; STEROIDOGENESIS; SURVIVAL RATE; SURVIVAL TIME; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; VIRILIZATION;

ADENOMA; ADRENAL CORTEX; CARCINOMA; MOLECULAR;

ADRENAL CORTEX NEOPLASMS; HUMANS;

EID: 84885936213     PISSN: 07402570     EISSN: 19301111     Source Type: Journal    
DOI: 10.1053/j.semdp.2013.07.001     Document Type: Article

References (145)

1. Dobbie J.W., Symington T. The human adrenal gland with special reference to the vasculature. J Endocrinol 1966, 34:479-489.
2. Nguyen A.D., Conley A.J. Adrenal androgens in humans and nonhuman primates: production, zonation and regulation. Endocr Dev 2008, 13:33-54.
3. Keegan C.E., Hammer G.D. Recent insights into organogenesis of the adrenal cortex. Trends Endocrinol Metab 2002, 13:200-208.
4. Beuschlein F., Keegan C.E., Bavers D.L., et al. SF-1, DAX-1, and acd: molecular determinants of adrenocortical growth and steroidogenesis. Endocr Res 2002, 28:597-607.
5. Miller W.L. Steroidogenic acute regulatory protein (StAR), a novel mitochondrial cholesterol transporter. Biochim Biophys Acta 2007, 1771:663-676.
6. Willenberg H.S., Schinner S., Ansurudeen I. New mechanisms to control aldosterone synthesis. Horm Metab Res 2008, 40:435-441.
7. Soon P.S., McDonald K.L., Robinson B.G., et al. Molecular markers and the pathogenesis of adrenocortical cancer. Oncologist 2008, 13:548-561.
8. l'Allemand D., Penhoat A., Blum W., et al. Is there a local IGF-system in human adrenocortical cells?. Mol Cell Endocrinol 1998, 140:169-173.
9. Albertin G., Forneris M., Aragona F., et al. Expression of adrenomedullin and its receptors in the human adrenal cortex and aldosteronomas. Int J Mol Med 2001, 8:423-426.
10. Vanttinen T., Liu J., Kuulasmaa T., et al. Expression of activin/inhibin signaling components in the human adrenal gland and the effects of activins and inhibins on adrenocortical steroidogenesis and apoptosis. J Endocrinol 2003, 178:479-489.
11. Haidan A., Bornstein S.R., Glasow A., et al. Basal steroidogenic activity of adrenocortical cells is increased 10- fold by coculture with chromaffin cells. Endocrinology 1998, 139:772-780.
12. Haidan A., Bornstein S.R., Liu Z., et al. Expression of adrenocortical steroidogenic acute regulatory (StAR) protein is influenced by chromaffin cells. Mol Cell Endocrinol 2000, 165:25-32.
13. Rossi G.P. Prevalence and diagnosis of primary aldosteronism. Curr Hypertens Rep 2010, 12:342-348.
14. Young W.F. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf) 2007, 66:607-618.
15. Willenberg H.S., Spath M., Maser-Gluth C., et al. Sporadic solitary aldosterone- and cortisol-co-secreting adenomas: endocrine, histological and genetic findings in a subtype of primary aldosteronism. Hypertens Res 2010, 33:467-472.
16. Bourdeau I., Lampron A., Costa M.H., et al. Adrenocorticotropic hormone-independent Cushing's syndrome. Curr Opin Endocrinol Diabetes Obes 2007, 14:219-225.
17. Christopoulos S., Bourdeau I., Lacroix A. Aberrant expression of hormone receptors in adrenal Cushing's syndrome. Pituitary 2004, 7:225-235.
18. Chabre O., Liakos P., Vivier J., et al. Cushing's syndrome due to a gastric inhibitory polypeptide-dependent adrenal adenoma: insights into hormonal control of adrenocortical tumorigenesis. J Clin Endocrinol Metab 1998, 83:3134-3143.
19. Carlson H.E. Human adrenal cortex hyperfunction due to LH/hCG. Mol Cell Endocrinol 2007, 269:46-50.
20. Lacroix A., N'Diaye N., Mircescu H., et al. The diversity of abnormal hormone receptors in adrenal Cushing's syndrome allows novel pharmacological therapies. Braz J Med Biol Res 2000, 33:1201-1209.
21. Carney J.A. The Carney complex (myxomas, spotty pigmentation, endocrine overactivity, and schwannomas). Dermatol Clin 1995, 13:19-26.
22. Stratakis C.A. Genetics of adrenocortical tumors: Carney complex. Ann Endocrinol (Paris) 2001, 62:180-184.
23. Bertherat J. Carney complex (CNC). Orphanet J Rare Dis 2006, 1:21.
24. Nimkarn S., New M.I. Steroid 11beta- hydroxylase deficiency congenital adrenal hyperplasia. Trends Endocrinol Metab 2008, 19:96-99.
25. Bachelot A., Chakthoura Z., Rouxel A., et al. Classical forms of congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults. Horm Res 2008, 69:203-211.
26. Torresani T., Biason-Lauber A. Congenital adrenal hyperplasia: diagnostic advances. J Inherit Metab Dis 2007, 30:563-575.
27. Goncalves J., Friaes A., Moura L. Congenital adrenal hyperplasia: focus on the molecular basis of 21-hydroxylase deficiency. Expert Rev Mol Med 2007, 9:1-23.
28. Bhangoo A., Anhalt H., Ten S., et al. Phenotypic variations in lipoid congenital adrenal hyperplasia. Pediatr Endocrinol Rev 2006, 3:258-271.
29. Merke D.P., Bornstein S.R. Congenital adrenal hyperplasia. Lancet 2005, 365:2125-2136.
30. Saeger W., Reinhard K., Reinhard C. Hyperplastic and tumorous lesions of the adrenals in an unselected autopsy series. Endocr Pathol 1998, 9:235-239.
31. Reinhard C., Saeger W., Schubert B. Adrenocortical nodules in post-mortem series. Development, functional significance, and differentiation from adenomas. Gen Diagn Pathol 1996, 141:203-208.
32. Bovio S., Cataldi A., Reimondo G., et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest 2006, 29:298-302.
33. Kloos R.T., Gross M.D., Francis I.R., et al. Incidentally discovered adrenal masses. Endocr Rev 1995, 16:460-483.
34. Beuschlein F., Reincke M. Adrenocortical tumorigenesis. Ann N Y Acad Sci 2006, 1088:319-334.
35. Dobbie J.W. Adrenocortical nodular hyperplasia. The ageing adrenal. J Pathol 1969, 99:1-18.
36. Nieman L.K. Approach to the patient with an adrenal incidentaloma. J Clin Endocrinol Metab 2010, 95:4106-4113.
37. Beuschlein F., Reincke M., Karl M., et al. Clonal composition of human adrenocortical neoplasms. Cancer Res 1994, 54:4927-4932.
38. Gicquel C., Leblond-Francillard M., Bertagna X., et al. Clonal analysis of human adrenocortical carcinomas and secreting adenomas. Clin Endocrinol (Oxf) 1994, 40:465-477.
39. Diaz-Cano S.J., de Miguel M., Blanes A., et al. Clonality as expression of distinctive cell kinetics patterns in nodular hyperplasias and adenomas of the adrenal cortex. Am J Pathol 2000, 156:311-319.
40. Favre L., Jacot-des-Combes E., Morel P., et al. Primary aldosteronism with bilateral adrenal adenomas. Virchows Arch A 1980, 388:229-236.
41. Desai N., Kapoor A., Singh B.K., et al. Bilateral adrenal adenomas and persistent leukocytosis: a unique case of Cushing's syndrome. Am J Med 2006, 119:e3-e5.
42. Lack E.E. Tumors of the Adrenal Gland and Extra-Adrenal Paraganglia 1997, Armed Forces Institute of Pathology, Washington DC. Third Series.
43. Brennan M.F. Adrenocortical carcinoma. CA Cancer J Clin 1987, 37:348-353.
44. Correa P., Chen V.W. Endocrine gland cancer. Cancer 1995, 75:338-352.
45. Lubitz J.A., Freeman L., Okun R. Mitotane use in inoperable adrenal cortical carcinoma. J Am Med Assoc 1973, 223:1109-1112.
46. Hutter A.M.J., Kayhoe D.E. Adrenal cortical carcinoma. Am J Med 1966, 41:572-580.
47. Ibanez ML. The Pathology of Adrenal Cortical Carcinomas. Study of 22 cases. Endocrine and Nonendocrine Hormone-Producing Tumors. Chicago: Year Book Medical Publishers; 1971, 231-239.
48. MacFarlane D.A. Cancer of the adrenal cortex. The natural history, prognosis and treatment in a study of fifty-five cases. Ann R Coll Surg Engl 1958, 23:155-186.
49. Aspinall S.R., Imisairi A.H., Bliss R.D., et al. How is adrenocortical cancer being managed in the UK?. Ann R Coll Surg Engl 2009, 91:489-493.
50. Paton B.L., Novitsky Y.W., Zerey M., et al. Outcomes of adrenal cortical carcinoma in the United States. Surgery 2006, 140:914-920. ([discussion 919-920]).
51. Fassnacht M., Johanssen S., Fenske W., et al. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab 2010, 95:4925-4932.
52. Schulick R.D., Brennan M.F. Adrenocortical carcinoma. World J Urol 1999, 17:26-34.
53. Ng L., Libertino J.M. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol 2003, 169:5-11.
54. Zografos G.C., Driscoll D.L., Karakousis C.P., et al. Adrenal adenocarcinoma: a review of 53 cases. J Surg Oncol 1994, 55:160-164.
55. Hough A.J., Hollifield J.W., Page D.L., et al. Prognostic factors in adrenal cortical tumours. Am J Clin Pathol 1979, 72:390-399.
56. Lack E.E., Travis W.D., Oertel J.E. Adrenal cortical neoplasms. Pathology of the Adrenal Glands 1990, 115-171. Churchill Livingstone, New York. E.E. Lack (Ed.).
57. Papotti M., Volante M., Duregon E., et al. Adrenocortical tumors with myxoid features: a distinct morphologic and phenotypical variant exhibiting malignant behavior. Am J Surg Pathol 2010, 34:973-983.
58. Van Slooten H., Schaberg A., Smeenk D., et al. Morphologic characteristics of benign and malignant adrenocortical tumors. Cancer 1985, 55:766-773.
59. Weiss L.M. Comparable histologic study of 43 metastasizing and non metastasizing adrenocortical tumors. Am J Surg Pathol 1984, 8:163-169.
60. Weiss L.M., Medeiros L.J., Vickery A.L. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 1989, 13:202-206.
61. Lau S.K., Weiss L.M. The Weiss system for evaluating adrenocortical neoplasms: 25 years later. Hum Pathol 2009, 40:757-768.
62. Aubert S., Wacrenier A., Leroy X., et al. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol 2002, 26:1612-1619.
63. van't Sant H.P., Bouvy N.D., Kazemier G., et al. The prognostic value of two different histopathological scoring systems for adrenocortical carcinomas. Histopathology 2007, 51:239-245.
64. Volante M., Bollito E., Sperone P., et al. Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. Histopathology 2009, 55:535-543.
65. Arola J., Salmenkivi K., Liu J., et al. p53 and Ki67 in adrenocortical tumors. Endocr Res 2000, 26:861-865.
66. McNicol A.M., Struthers A.J., Nolan C.E., et al. Proliferation in adrenocortical tumors: correlation with clinical outcome and p53 status. Endocr Pathol 1997, 8:29-36.
67. Sasano H., Imatani A., Shizawa S., et al. Cell proliferation and apoptosis in normal and pathologic human adrenal. Mod Pathol 1995, 8:11-17.
68. McNicol A.M., Nolan C.E., Struthers A.J., et al. Expression of p53 in adrenocortical tumours: clinicopathological correlations. J Pathol 1997, 181:146-152.
69. Soon P.S., Gill A.J., Benn D.E., et al. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. Endocr Relat Cancer 2009, 16:573-583.
70. Schmitt A., Saremaslani P., Schmid S., et al. IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours. Histopathology 2006, 49:298-307.
71. Sredni S.T., Alves V.A., Latorre Mdo R., et al. Adrenocortical tumours in children and adults: a study of pathological and proliferation features. Pathology 2003, 35:130-135.
72. Sasano H., Suzuki T., Sano T., et al. Adrenocortical oncocytoma. A true nonfunctioning adrenocortical tumor. Am J Surg Pathol 1991, 15:949-956.
73. Xiao G.Q., Pertsemlidis D.S., Unger P.D. Functioning adrenocortical oncocytoma: a case report and review of the literature. Ann Diagn Pathol 2005, 9:295-297.
74. Golkowski F., Buziak-Bereza M., Huszno B., et al. The unique case of adrenocortical malignant and functioning oncocytic tumour. Exp Clin Endocrinol Diabetes 2007, 115:401-404.
75. Ohtake H., Kawamura H., Matsuzaki M., et al. Oncocytic adrenocortical carcinoma. Ann Diagn Pathol 2010, 14:204-208.
76. Bisceglia M., Ludovico O., Di Mattia A., et al. Adrenocortical oncocytic tumors: report of 10 cases and review of the literature. Int J Surg Pathol 2004, 12:231-243.
77. Wong D.D., Spagnolo D.V., Bisceglia M., et al. Oncocytic adrenocortical neoplasms-a clinicopathologic study of 13 new cases emphasizing the importance of their recognition. Hum Pathol 2011, 42:489-499.
78. Morimoto R., Satoh F., Murakami O., et al. Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocr J 2008, 55:49-55.
79. Terzolo M., Boccuzzi A., Bovio S., et al. Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumors. Urology 2001, 57:176-182.
80. Giordano T.J., Kuick R., Else T., et al. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res 2009, 15:668-676.
81. Turbendian H.K., Strong V.E., Hsu M., et al. Adrenocortical carcinoma: the influence of large vessel extension. Surgery 2010, 148:1057-1064. ([discussion 1064]).
82. Sobin L.H., Wittekind C. TNM Classification of Malignant Tumours 2002, Wiley-Liss, New York. Sixth ed.
83. Fassnacht M., Johanssen S., Quinkler M., et al. Limited prognostic value of the 2004 International union against cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer 2009, 115:243-250.
84. Lughezzani G., Sun M., Perrotte P., et al. The European Network for the study of adrenal tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer 2010, 46:713-719.
85. Miller B.S., Gauger P.G., Hammer G.D., et al. Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade. Langenbeck's Arch Surg 2010, 395:955-961.
86. Haak H.R., Fleuren G.J. Neuroendocrine differentiation of adrenocortical tumors. Cancer 1995, 75:860-864.
87. Sangoi A.R., McKenney J.K. A tissue microarray-based comparative analysis of novel and traditional immunohistochemical markers in the distinction between adrenal cortical lesions and pheochromocytoma. Am J Surg Pathol 2010, 34:423-432.
88. Ghorab Z., Jorda M., Ganjei P., et al. Melan A (A103) is expressed in adrenocortical neoplasms but not in renal cell and hepatocellular carcinomas. Appl Immunohistochem Mol Morphol 2003, 11:330-333.
89. Munro L.M., Kennedy A., McNicol A.M. The expression of inhibin/activin subunits in the human adrenal cortex and its tumours. J Endocrinol 1999, 161:341-347.
90. Soon P.S., Sidhu S.B. Adrenocortical carcinoma. Cancer Treat Res 2010, 153:187-210.
91. Soon P.S., Sidhu S.B. Molecular basis of adrenocortical carcinomas. Minerva Endocrinol 2009, 34:137-147.
92. Opocher G., Schiavi F., Cicala M.V., et al. Genetics of adrenal tumors. Minerva Endocrinol 2009, 34:107-121.
93. Bussey K.J., Demeure M.J. Genomic and expression profiling of adrenocortical carcinoma: application to diagnosis, prognosis and treatment. Future Oncol 2009, 5:641-655.
94. Stratakis C.A., Boikos S.A. Genetics of adrenal tumors associated with Cushing's syndrome: a new classification for bilateral adrenocortical hyperplasias. Nat Clin Pract Endocrinol Metab 2007, 3:748-757.
95. Giordano T.J. Molecular pathology of adrenal cortical tumors: separating adenomas from carcinomas. Endocr Pathol 2006, 17:355-363.
96. Cohen M.M. Beckwith-Wiedemann syndrome: historical, clinicopathological, and etiopathogenetic perspectives. Pediatr Dev Pathol 2005, 8:287-304.
97. Nichols K.E., Malkin D., Garber J.E., et al. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 2001, 10:83-87.
98. Roos A., Groen E.J., van Beek A.P. Cushing's syndrome due to unilateral multiple adrenal adenomas as an extraintestinal manifestation of familial adenomatous polyposis. Int J Colorectal Dis 2009, 24:239.
99. Wakatsuki S., Sasano H., Matsui T., et al. Adrenocortical tumor in a patient with familial adenomatous polyposis: a case associated with a complete inactivating mutation of the APC gene and unusual histological features. Hum Pathol 1998, 29:302-306.
100. Machens A., Schaaf L., Karges W., et al. Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. Clin Endocrinol (Oxf) 2007, 67:613-622.
101. Langer P., Cupisti K., Bartsch D.K., et al. Adrenal involvement in multiple endocrine neoplasia type 1. World J Surg 2002, 26:891-896.
102. Sidhu S., Marsh D.J., Theodosopoulos G., et al. Comparative genomic hybridization analysis of adrenocortical tumors. J Clin Endocrinol Metab 2002, 87:3467-3474.
103. Gicquel C., Bertagna X., Gaston V., et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res 2001, 61:6762-6767.
104. Russell A.J., Sibbald J., Haak H., et al. Increasing genome instability in adrenocortical carcinoma progression with involvement of chromosomes 3, 9 and X at the adenoma stage. Br J Cancer 1999, 81:684-689.
105. Stephan E.A., Chung T.H., Grant C.S., et al. Adrenocortical carcinoma survival rates correlated to genomic copy number variants. Mol Cancer Ther 2008, 7:425-431.
106. Kjellman M., Roshani L., Teh B.T., et al. Genotyping of adrenocortical tumors: very frequent deletions of the MEN1 locus in 11q13 and of a 1-centimorgan region in 2p16. J Clin Endocrinol Metab 1999, 84:730-735.
107. Reincke M., Mora P., Beuschlein F., et al. Deletion of the adrenocorticotropin receptor gene in human adrenocortical tumors: implications for tumorigenesis. J Clin Endocrinol Metab 1997, 82:3054-3058.
108. Libe R., Groussin L., Tissier F., et al. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin Cancer Res 2007, 13:844-850.
109. Reincke M., Karl M., Travis W.H., et al. p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J Clin Endocrinol Metab 1994, 78:790-794.
110. Ohgaki H., Kleihues P., Heitz P.U. p53 mutations in sporadic adrenocortical tumors. Int J Cancer 1993, 54:408-410.
111. Varley J.M., McGown G., Thorncroft M., et al. Are there low-penetrance TP53 alleles? evidence from childhood adrenocortical tumors. Am J Hum Genet 1999, 65:995-1006.
112. Wagner J., Portwine C., Rabin K., et al. High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst 1994, 86:1707-1710.
113. Latronico A.C., Pinto E.M., Domenice S., et al. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J Clin Endocrinol Metab 2001, 86:4970-4973.
114. Schulte K.M., Mengel M., Heinze M., et al. Complete sequencing and messenger ribonucleic acid expression analysis of the MEN I gene in adrenal cancer. J Clin Endocrinol Metab 2000, 85:441-448.
115. Boulle N., Logie A., Gicquel C., et al. Increased levels of insulin-like growth factor II (IGF-II) and IGF- binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. J Clin Endocrinol Metab 1998, 83:1713-1720.
116. Gicquel C., Bertagna X., Schneid H., et al. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J Clin Endocrinol Metab 1994, 78:1444-1453.
117. Ilvesmaki V., Kahri A.I., Miettinen P.J., et al. Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas. J Clin Endocrinol Metab 1993, 77:852-858.
118. Gao Z.H., Suppola S., Liu J., et al. Association of H19 promoter methylation with the expression of H19 and IGF-II genes in adrenocortical tumors. J Clin Endocrinol Metab 2002, 87:1170-1176.
119. Gicquel C., Raffin-Sanson M.L., Gaston V., et al. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J Clin Endocrinol Metab 1997, 82:2559-2565.
120. Voutilainen R., Ilvesmaki V., Ariel I., et al. Parallel regulation of parentally imprinted H19 and insulin-like growth factor-II genes in cultured human fetal adrenal cells. Endocrinology 1994, 134:2051-2056.
121. Bonnet S., Gaujoux S., Launay P., et al. Wnt/beta-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors. J Clin Endocrinol Metab 2011, 96:E419-E426.
122. Berthon A., Sahut-Barnola I., Lambert-Langlais S., et al. Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Hum Mol Genet 2010, 19:1561-1576.
123. Bielinska M., Parviainen H., Kiiveri S., et al. Origin and molecular pathology of adrenocortical neoplasms. Vet Pathol 2009, 46:194-210.
124. Tadjine M., Lampron A., Ouadi L., et al. Frequent mutations of beta-catenin gene in sporadic secreting adrenocortical adenomas. Clin Endocrinol (Oxf) 2008, 68:264-270.
125. Tissier F., Cavard C., Groussin L., et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res 2005, 65:7622-7627.
126. Latronico A.C. Role of ACTH receptor in adrenocortical tumor formation. Braz J Med Biol Res 2000, 33:1249-1252.
127. Light K., Jenkins P.J., Weber A., et al. Are activating mutations of the adrenocorticotropin receptor involved in adrenal cortical neoplasia?. Life Sci 1995, 56:1523-1527.
128. Demeure M.J., Doffek K.M., Komorowski R.A., et al. Gip-2 codon 179 oncogene mutations: absent in adrenal cortical tumors. World J Surg 1996, 20:928-931. ([discussion 931-922]).
129. Gicquel C., Dib A., Bertagna X., et al. Oncogenic mutations of alpha-Gi2 protein are not determinant for human adrenocortical tumourigenesis. Eur J Endocrinol 1995, 133:166-172.
130. Laurell C., Velazquez-Fernandez D., Lindsten K., et al. Transcriptional profiling enables molecular classification of adrenocortical tumours. Eur J Endocrinol 2009, 161:141-152.
131. de Reynies A., Assie G., Rickman D.S., et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol 2009, 27:1108-1115.
132. Fernandez-Ranvier G.G., Weng J., Yeh R.F., et al. Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling. Arch Surg 2008, 143:841-846. ([discussion 846]).
133. Slater E.P., Diehl S.M., Langer P., et al. Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. Eur J Endocrinol 2006, 154:587-598.
134. Velazquez-Fernandez D., Laurell C., Geli J., et al. Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. Surgery 2005, 138:1087-1094.
135. de Fraipont F., El Atifi M., Cherradi N., et al. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab 2005, 90:1819-1829.
136. Giordano T.J., Thomas D.G., Kuick R., et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol 2003, 162:521-531.
137. Barlaskar F.M., Spalding A.C., Heaton J.H., et al. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J Clin Endocrinol Metab 2009, 94:204-212.
138. Schmitz K.J., Helwig J., Bertram S., et al. Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and malignant adrenocortical tumours. J Clin Pathol 2011, 64:529-535.
139. Patterson E.E., Holloway A.K., Weng J., et al. MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer 2011, 117:1630-1639.
140. Ozata D.M., Caramuta S., Velazquez-Fernandez D., et al. The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocr Relat Cancer 2011, 18:643-655.
141. Faucz F.R., Stratakis C.A. Adrenal cortex and micro-RNAs: an update. Cell Cycle 2010, 9:4039-4040.
142. Bimpaki E.I., Iliopoulos D., Moraitis A., et al. MicroRNA signature in massive macronodular adrenocortical disease and implications for adrenocortical tumourigenesis. Clin Endocrinol 2010, 72:744-751.
143. Soon P.S., Tacon L.J., Gill A.J., et al. miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clin Cancer Res 2009, 15:7684-7692.
144. Iliopoulos D., Bimpaki E.I., Nesterova M., et al. MicroRNA signature of primary pigmented nodular adrenocortical disease: clinical correlations and regulation of Wnt signaling. Cancer Res 2009, 69:3278-3282.
145. Sobin L.H., Gospodarowicz M., Wittekind C. TNM Classification of Malignant Tumours 2009, Wiley-Blackwell, Hoboken, New Jersey. 7th ed.